8-K: Neuronetics Announces $18 Million Public Offering of Common Stock

Neuronetics, Inc. has priced its public offering of 8,000,000 shares of common stock at $2.25 per share, expecting gross proceeds of $18 million.

Summary

• Neuronetics, Inc. has announced an underwritten public offering of its common stock.
• The offering consists of 8,000,000 shares priced at $2.25 per share, resulting in approximately $18 million in gross proceeds before deductions.
• The underwriter, Canaccord Genuity LLC, has been granted a 30-day option to purchase up to an additional 1,200,000 shares.
• The company anticipates net proceeds of approximately $16.355 million, or $18.893 million if the underwriter exercises the option in full.
• Neuronetics plans to use the net proceeds for general corporate purposes, including sales and marketing, research and development, potential acquisitions, inventory purchases, and working capital.
• The offering is expected to close around February 10, 2025, contingent upon customary closing conditions.
• The offering is made under a prospectus supplement related to a shelf registration statement filed on November 9, 2022, and declared effective on November 14, 2022.

Sentiment

Score: 5

Explanation: The sentiment is neutral. The announcement is a standard financial transaction (public offering) with both potential benefits (funding) and risks (dilution). The company's future prospects depend on how effectively it uses the raised capital.

Positives

• The public offering will provide Neuronetics with approximately $16.355 million to $18.893 million in net proceeds to fund its operations.
• The funds can be used for various purposes, including sales and marketing, research and development, and potential acquisitions, providing flexibility for growth.
• The offering is fully underwritten, providing certainty of funding assuming customary closing conditions are met.
• The underwriter's option to purchase additional shares could increase the total proceeds to the company.

Negatives

• The offering will dilute existing shareholders' ownership.
• The company is relying on raising capital through the sale of shares, which may indicate a lack of sufficient internally generated funds.
• The company's stock price may be negatively impacted by the increased supply of shares in the market.
• The company has a history of losses, and the offering is needed to continue operations.

Risks

• The offering is subject to market conditions, and there is no guarantee that it will be completed on the anticipated terms or at all.
• The company's ability to execute its business strategy and achieve profitable operations is subject to various risks and uncertainties.
• The company relies on the sale and use of the NeuroStar Advanced Therapy System to generate revenues, which is subject to market demand and competition.
• The company's ability to obtain and maintain intellectual property protection for its technology is crucial for its long-term success.
• The company's self-sustainability and existing cash balances are subject to various factors, including its ability to manage expenses and generate revenue.
• The company's ability to achieve cash flow break-even in the third quarter of 2025 is subject to various risks and uncertainties.

Future Outlook

The Company expects to use the net proceeds from the Offering for general corporate purposes, including but not limited to sales and marketing, research and development activities, financing of potential acquisitions or establishment of healthcare practices, purchases of inventory, general and administrative matters, working capital and capital expenditures.

Industry Context

The announcement reflects a common strategy for companies in the medical device and neuroscience sectors to raise capital for growth initiatives, especially given the capital-intensive nature of R&D, sales, and market expansion.

Comparison to Industry Standards

• The size of the offering ($18 million) is relatively small compared to larger, more established medical device companies, but is typical for smaller, growth-stage companies.
• Comparable companies like transcranial magnetic stimulation (TMS) providers or other neuro-modulation technology firms might undertake similar offerings to fund expansion or clinical trials.
• The use of proceeds for sales and marketing, R&D, and potential acquisitions aligns with industry norms for companies seeking to expand their market presence and product offerings.
• The underwriting agreement with Canaccord Genuity LLC is a standard arrangement, with typical terms and conditions for such offerings.

Stakeholder Impact

• Shareholders will experience dilution due to the issuance of new shares.
• The company's employees may benefit from increased investment in sales and marketing, research and development, and potential acquisitions.
• Customers may benefit from improved products and services as a result of the company's increased investment in research and development.
• The company's suppliers may benefit from increased orders as a result of the company's growth.

Next Steps

• The company will file a final prospectus supplement with the SEC.
• The offering is expected to close on or about February 10, 2025, subject to customary closing conditions.
• Neuronetics will use the net proceeds from the offering for general corporate purposes.

Key Dates